Australia markets open in 18 minutes

ABBV Feb 2022 80.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
41.200.00 (0.00%)
As of 01:26PM EST. Market open.
Full screen
Loading interactive chart…
  • Zacks

    AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study

    AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

  • Zacks

    Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study

    Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.

  • Bloomberg

    Alvotech to Go Public Through Oaktree SPAC Merger

    (Bloomberg) -- Alvotech Holdings SA, a company developing and manufacturing so-called biosimilar drugs, is going public in the U.S. through a merger with a blank-check firm backed by Oaktree Capital Management.Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsEven in the Metaverse, Not All Identities Are Created EqualThe $300 Billion Plan to Bring Green Power to China’s MegacitiesMeet the New